Navigation Links
Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008
Date:11/6/2008

the nine months ended September 30, 2008, cash generated from operations was $23.4 million, while purchases of capital equipment for the same period totaled $7.0 million. The quarter ended with bad debt expense at 3% of total revenues and average days sales outstanding of 53 days.

"Our recent facilities expansion, coupled with recruiting and hiring efforts, is expected to nearly double our capacity to manage the increasing number of patient cases, supporting our continued growth for the foreseeable future," said Sam Riccitelli, Genoptix EVP and COO. "We have added eight new sales representatives during the quarter, bringing the total number to 52 and nearing our goal for the year. We also welcomed six additional hematopathologists to our Cartesian medical group. This brings our group to a total count of 25 on-site professionals to service our more than 950 currently ordering physicians nationwide, as we continue to effectively pace our expansion relative to our growing customer base."

Performance Outlook

Based on results over the past nine months, Genoptix is adjusting its performance outlook upward for the full-year 2008. The Company now expects revenues of approximately $112 million, up from the most recent guidance of between $105 and $108 million.

Net income expectations for the year are now approximately $29 million, which includes the $5.8 million net tax benefit recognized in the first nine months of the year and assumes a tax rate of approximately 45% in the fourth quarter of 2008. This guidance also incorporates an estimated $7 million in non-cash stock-based compensation for 2008.

The Company now expects diluted GAAP EPS for the full year 2008 to be between $1.60 and $1.65 on an estimated 17.7 million shares. This includes $0.33 per share of net tax benefit recognized in the first nine months of the year.

Based on continued infrastructure expansion and implementation of its strategic plan, the Company continues to
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
4. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
5. Genoptix Announces Pricing of Secondary Public Offering
6. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
7. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
8. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
9. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
10. Genoptix Reports Strong Financial Results for First Quarter 2008
11. Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
Breaking Medicine News(10 mins):Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3
...r a long period of time may decrease brain volume,...he American Academy of Neurology's 59th Annual Me...e study involved MRI scans of 1,839 people from th...te drinkers (eight to 14 drinks per week), or high...
... backup supply of stem cells that can repair the m...r sense of smell. These reservists normally lie a...ie, the scientists say, the stem cells jump into a...se, explains lead author Randall Reed, Ph.D., a pr...
... the University of Rhode Island have demonstrated ...using a short piece of protein that acts like a na...ording to a report in the Proceedings of the Natio... abdomen of a mouse, find its way into the blood a...
...pies or simply investigate how organisms develop, ... biological science's toughest assignments: keepin... Stem cells have notoriously finicky tastes, a...egin morphing into specific cell types. U...
...w approaches to funding are needed to support the ..., say health policy experts. Providing q...ient often ends in the blame game between Federal ...ann Yen, Visiting Fellow with the Menzies Centre f...
...dy shows that repeated treatments of botulinum tox...lts in a significant decrease in spasticity, pain...bs following stroke, according to research from a ...life for post-stroke patients suffering from spast...
Other Medicine News:Health News:Drinking Heavy Amounts of Alcohol Shrinks Your Brain 2Health News:When Smell Cells Fail They Call In Stem Cell Reserves 2Health News:Novel Technology to Locate and Treat Tumors 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 3Health News:Pain and Intensity Of Post-stroke Spasticity Decreased by Botox Treatment 2
(Date:12/4/2009)Workers Ensure Emergency Deliveries are Transported ,, PHILADELPHIA, Dec. 4 Teamster members employed by the Philadelphia chapter of the American Red Cross are hard at work educating the public abo
(Date:12/4/2009)SALT LAKE CITY, Dec. 4 Dynatronics Corporation (Nasdaq: DYNT ) announced it has signed a sole-source vendor agreement to provide therapy equipment and rehab supplies to Benchmark Physical Therapy wi
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
Breaking Medicine Technology:Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4The future of schizophrenia 57009 1The future of schizophrenia 57009 2The future of schizophrenia 57009 3The future of schizophrenia 57009 4The future of schizophrenia 57009 5The Dr Oz Show Premieres Today Nationwide 57005 1The Dr Oz Show Premieres Today Nationwide 57005 2The Dr Oz Show Premieres Today Nationwide 57005 3The Dr Oz Show Premieres Today Nationwide 57005 4The Dr Oz Show Premieres Today Nationwide 57005 5Asian Countries Cannot Afford To Ignore the Cost of Rheumatoid Arthritis 57003 1Asian Countries Cannot Afford To Ignore the Cost of Rheumatoid Arthritis 57003 2Asian Countries Cannot Afford To Ignore the Cost of Rheumatoid Arthritis 57003 3Asian Countries Cannot Afford To Ignore the Cost of Rheumatoid Arthritis 57003 4Asian Countries Cannot Afford To Ignore the Cost of Rheumatoid Arthritis 57003 5
...and TAX 324 Published, BRIDGEWATER, N.J., Oct. 24...wo clinical studies demonstrating that,Taxotere(R)...cisplatin and,5- fluorouracil for induction therap... patients with locally advanced squamous cell carc...n the October 25 issue of the New,England Journal ...
...d sleep behavior,disorders, ROCHESTER, Minn., Oct... diagnosing and treating patients with a,variety o...ea and sleep,behavior disorders, at CHEST 2007, th...Physicians in Chicago on Oct. 20-25. The following...re than 12 million people in the United States hav...
Other Medicine Technology:Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 2Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 3Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 4Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 7Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 3Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 4
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: